



This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.







## Agenda

01

02

03

04



**Industry Overview** 



**Company Overview** 

The Quick Heal Advantage

ĝ ĝ ĝ

Q3FY22 Earnings Highlights

05

Q3FY22 Earnings







## INDUSTRY OVERVIEW


Rapid digitization has enhanced need for greater cybersecurity investments













**1.32**b

People enrolled in the world's largest unique digital identity program



Users engaged in social media

**639**m



Application downloads in 2020

**30**b




Average cost to subscriber per GB wireless data

Rs.**6.98** 

Source: The Ministry of Electronics and Information Technology, TRAI, Government of India, Statista, Google report – Insights for Brands, KPMG Report – Fintech In India, India Data Diviner – Macquarie, Nokia MBIT, Goldman Sachs Investment Research – Portfolio Strategy Research (Sept 19, 2021)

#### Cyber attacks continue to grow in scale and sophistication







₹ 165 mln The Average cost of a data breach in India. An increase of **17.85%** from 2020

Source: Quick Heal Threat Report 2021

Source: IBM

Cyber-attacks that grabbed headlines



Log4j security flaw puts the entire internet at risk- Indian Express (December 14, 2021)

> Google warns crypto miners are hacking users' cloud accounts- CNBCTV18 (November 30, 2021)

Indian gamers lost Rs.7,894 on an average due to cyberattacks- The Mint (November 15, 2021)

Cybercrimes in India during pandemic have gone up by 500 per cent: CDS Gen Bipin Rawat – Economic times (November 12, 2021)

India 3rd in data breaches till Nov-Times of India (December 17, 2021)


Indian PM Modi's Twitter hacked with bitcoin tweet-BBC News (December 12, 2021)


Source: Reputed News Outlets

#### 2021 Cyber threat landscape shows that...









Source: Segrite Annual Threat Report 2022

Source: Segrite Annual Threat Report 2022

Source: Quick Heal Annual Threat Report 2022



#### Cyber threat predictions for 2022 and beyond

01

'Karakurt' Extortion threat emerges focusing on data theft for ransom 02

Fileless Malware Infection likely to advance and escape security products detection 03

Rise of double and triple-vector extortion technique demanding money for encrypted files 04

Cobalt strike attacks gets more sophisticated with new features and MITRE framework

05

Rise in Covid-themebased attacks with the use of more sophisticated social engineering techniques 06

Increase in supply chain attacks leading to ransomware and other complex exploitations

07

Critical zero-day vulnerabilities on the rise

18

Rise in the new vulnerabilities on the server-side technologies

09

Rise of IoT attacks on vulnerable companion applications 10

Rise of social media credential stealer applications

11

Use of AI voice cloning tricks and Deepfake techniques to steel sensitive data

12

Rise of Ransomwareasa-Service attacks targeting critical sectors

13

Rise in Linux side vulnerabilities with the release of WSL feature 14

Resurrection of old vulnerabilities using ransomware via phishing emails and malicious files


1

Rise in targeted surveillance attacks with variants of different spywares

Source: Segrite Threat Predictions 2022

## Quick Heal is well positioned to leverage its strengths to capture the future opportunities









COMPANY OVERVIEW

#### Company at a glance





#### Vision

To be the trusted global leader in securing the digital world

#### **Mission**


Secure our customers by providing innovative, most preferred and valued security solutions, services and knowledge

Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization

#### Our journey





Over 25 years of simplifying security

## Scripting a new success story In the cybersecurity industry

#### **Quick Heal**





₹ **652** mln O3FY22 Revenue\*

#### SECRITE





₹**201** mln Q3FY22 Revenue\*















- India's first listed cybersecurity products company
- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Seqrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts and engineers leverages a combination of AI, cloud and patented technologies to deliver timely and advanced protection
- Solutions to secure across platforms


<sup>\*</sup>Based on net revenues before adjusting for sales incentives

#### The Cash Cow: Anti Virus Business




- Over 25 years into existence
- Market leadership with over 30% in the Indian market
- Robust Sales & Distribution network in India

# Revenue (INR Mn) 652 603 Q3FY20 Q3FY21 Q3FY22










#### Cybersecurity Startup incubated inhouse






- Incubated the enterprise cybersecurity through internal accruals
- Growth story for QH in the years to come
- Launching new products
- %Exports : ~18% of our Enterprise revenues
- Amount spent on R&D has been charged to P&L as per prudent accounting policies and good governance practices

ARR\* of over INR 800 Mn

#### **Shareholding Information**



**Shareholding structure – 31st December 2021** 



### **Shareholder Information** (as on 31st December 2021)

NSE Ticker	QUICKHEAL
BSE Ticker	539678
Market Cap (INR mln)	14,350
% Free-float	27.08%
Free-float market cap (INR mln)	3,886
Total Debt (INR mln)	-
Cash & Cash Equivalents (INR mln)	3,275
Shares Outstanding	5.79,56,601
3M ADTV (Shares)*	1,94,919
3M ADTV (INR mln)*	45.6
Industry	IT Software Products


\*Source: NSE



#### Strong threat detection and prevention capabilities...









Powers **SIGNATURE-LESS** and **SIGNATURE-BASED** detections


Our best and the most innovative malware hunting engine brings together the best of the best!













## ...with State-of-the-Art Research & Development leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers






## Committed to deliver exceptional



## customer experience

- Multi-lingual end user support in English, Hindi and several other major regional Indian languages
  - 2 Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms
    - Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



#### **Experienced Board of Directors**





Dr. Kailash Katkar MD & CEO

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar
Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Air Marshal (Retd) Bhushan Nilkanth Gokhale Independent Director

Served on the board of defense PSUs and adviser to government institutions. Appointed as Independent Security Advisor in Ministry of Home Affairs.



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi
Independent Director

Certified bank forensic accounting professional and anti – money laundering expert



Mr. Richard Stiennon Independent Director

Serves as Chief Research Analyst at IT-Harvest, and sits on the advisory boards of several start-ups. Has been the part of board of cybersecurity companies like Symantec, McAfee, Cisco, Microsoft and Trend Micro

#### ...along with strong Management...





Dr. Kailash Katkar *MD & CEO* 

#### **Co-founder of the Company**

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy.



Dr. Sanjay Katkar Joint MD & CTO

#### **Co-founder of the Company**

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune.

#### ...and seasoned Leadership team





Mr. Navin Sharma

Responsible for driving growth lead strategy through organic & inorganic channels.

Previously was the CFO with Sterlite Technologies for the technology business.

Navin has worked with RPG Group and Century Textiles and Industries Limited and brings vast experience in the areas of M&A, customer acquisition, financial planning and analysis and managing overseas operations.



Ms. Reetu Raina

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Sanjay Agrawal

Responsible for driving the overall product vision and strategy in line with market expectations.

Sanjay is an entrepreneurial engineering and product leader with two decades of experience and proven success in building cybersecurity products for the global markets.

A computer engineering graduate from University of Illinois, Sanjay holds a Ph.D. and M.S. from Stanford University in Electrical Engineering and Computer Science (EECS).

#### ...and seasoned Leadership team



Mr. Bibhuti Kar Head, R&D

Responsible for driving company's development efforts leading a team of talented engineering professionals and security researchers.

Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry.

An alumnus of IIT Kharagpur with a master's in ECE, he has worked on missile communication systems with DRDO.



Mr. Kuldeep Raina Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

Over two decades of diverse sales experience including leadership roles in cybersecurity companies.





Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

Over two decades of experience in FMCG, Beverages, Telecom and IT Industries.


## Strong brand recognition...



Certified and approved **by ICSA Labs** in 2021



Certified with
Advanced
Approved Endpoint
Protection by
AV-Test 2021





Best AV of 2020 at the 13th NCN Innovative Product Award 2021







Segrite

Endpoint

Security

Certified as 'Top

**Product'** for



Certified and approved **by ICSA Labs** in 2020



Certified as **'Top Product'** for
business users
by **'AV-Test'** in 2020



Certified as **'Top Product'** for
consumers
by **'AV-Test'** in 2020



Seqrite





Quick Heal Technologies

Recognized by

NASSCOM's DSCI

**'Cybersecurity** 

**in India'** 2019

**Product Pioneer** 

Granted Patent for Anti-Ransomware Technology 2019 U.S. Patent No. US20160378988A1

**Ouick Heal** 

**Technologies** 



Quick Heal Technologies

Granted Patent for its **Signatureless Behavior-based Detection Technology** 2019
U.S Patent No.
US20170124327A1

#### ...backed by Certifications, Patents and...

#### International & ISO Certifications















Cybersecurity Product
Pioneer in India

#### **Patented Technologies**

#### USPTO 10,387,649

Signatureless Behaviour-based Detection Technology

#### USPTO 10,311,234

Anti-Ransomware technology

#### USPTO 8,973,136

System and method for protecting computer systems from malware attacks

#### USPTO 8,914,908

A completely automated computer implemented system and method for piracy control based on update requests

#### USPTO 8,347,389

System for protecting devices against virus attacks

#### USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software

#### Securing the future through our community initiatives







*23,50,000*+

Lives directly impacted since 2016

#### **Cybersecurity**

- Cybersecurity Awareness
- Cyber Shiksha for Suraksha
- Street Plays



1,00,000+

Lives impacted since 2020

#### **Covid-19 Relief Initiatives**

- Free immunity boosters medicines to frontline workers
- Organised health camps and assisted in the smooth functioning of Covid-19 centres
- Donated medical vans to NGOs to heal tribal population
- Distribution of food grains during lockdown
- Distribution of PPE kits to NGOs
- Donated to PM Cares Fund









*45,000*+

Lives directly impacted since 2016

#### **Education**

 Life Skills Education for underprivileged children











## Quick Heal Academy to drive the next generation of cyber security experts





#### **Popular Courses**

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- ✓ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

#### **Offerings**



CORPORATE TRAINING



NEED-BASED TRAINING



WORKSHOPS & SEMINARS



CONNECTING CYBER ECO-SYSTEM

#### **Academy Partners**

#### **Chitkara University**

CHITKARA

MANAV RACHNA

W

Quantum

**B**SCI

A NASSCOM® Initiative

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program

#### **Quantum University**

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

#### Manav Rachna University

MoU with Manav Rachna University (MRU) for a joint B. Tech in Cyber Security & Threat Intelligence, programme

'Cyber Shikshaa Programme' an initiate of DSCI and Microsoft: Quick Heal as the training partner has targeted to train 5000 students across India creating cyber security awareness through online programme

#### **Sage University**

MoU with Sage University (Indore) for a joint B. Tech in Cyber Security programme

#### **Parul University**

MoU with Parul University, Vadodara for Joint B. Tech Programme (4 Years )





#### Q3FY22 Earnings Highlight







Q3FY22 Revenue at

₹796 mln

Up 14% from Q3FY21

#### **Diluted EPS**

Q3FY22 EPS at

**2.45** 

Up 17% from Q3FY21

#### **EBITDA**



Q3FY22 EBITDA at

₹205 mln

Up 24% from Q3FY21

**Retail** at

₹652 mln

Up 8% from Q3FY21

#### **PAT**

Q3FY22 PAT at

₹143 mln

Up 6% from Q3FY21

**Enterprise** at

₹201 mln

Up 11% from Q3FY21

#### Q3FY22 Revenue split







Enterprise + Government 23.6%



#### Q3FY22 – Consolidated Performance Highlights








<sup>\*</sup>As per Ind AS

#### 9MFY22 - Consolidated Performance Highlights





<sup>\*\*</sup>Note: There was a spill over of revenue of ₹ 300 mln from Q4FY20 in Q1FY21 due to non -availability of transport facilities due to lockdown

<sup>\*</sup>As per Ind AS

#### Q3FY22 Segment performance






#### Retail


**Enterprise & Government** 


Revenue break-up





Licenses Sold Analysis





#### 9MFY22 Segment performance







#### Retail


**Enterprise & Government** 


Revenue break-up





Licenses Sold Analysis





#### Q3FY22 – Profitability statement





DARTICIII ARS (# mln)	Standalone		Consolidated			
PARTICULARS (₹ mln)	Q3FY21	Q3FY22	% change	Q3FY21	Q3FY22	% change
Total Revenue	711.23	796.25	11.95%	698.75	796.16	13.94%
Direct Cost	26.18	32.42		26.39	32.40	
Gross Profit	685.05	763.83	11.50%	672.36	763.76	13.59%
Gross Margin	96.32%	95.93%	-39bps	96.22%	95.93%	-29bps
Operating Cost						
Research and Development (R&D)	170.09	213.04		170.09	213.04	
Sales and Marketing (S&M)	221.05	211.56		224.99	214.80	
General Administration (G&A)	136.45	134.77		112.65	131.12	
Total Expenditure	527.59	559.37	-6.02%	507.73	558.96	-10.09%
EBITDA	157.46	204.46	29.85%	164.63	204.80	24.40%
EBITDA Margin	22.14%	25.68%	354bps	23.56%	25.72%	216bps
Depreciation	49.56	45.41		49.57	45.43	
EBIT	107.90	159.05	47.41%	115.06	159.37	38.51%
EBIT Margin	15.17%	19.97%	480bps	16.47%	20.02%	355bps
Other Income	62.31	36.28		62.87	36.31	
Profit Before Tax (PBT after exceptional item)	170.21	195.33	14.76%	177.93	195.68	9.98%
Tax	42.99	52.52		43.32	52.81	
Profit After Tax (PAT)	127.22	142.81	12.25%	134.61	142.87	6.14%
PAT Margin	17.89%	17.94%	5bps	19.26%	17.94%	-132bps

#### 9MFY22 – Profitability statement





DARTICIU ARS (# mln)	S	tandalone		С	onsolidated	
PARTICULARS (₹ mln)	9MFY21	9MFY22	% change	9MFY21	9MFY22	% change
Total Revenue	2,274.23	2,378.00	4.56%	2,277.50	2,381.85	4.58%
Direct Cost	88.67	93.17		91.53	90.31	
Gross Profit	2,185.56	2,284.83	4.54%	2,185.97	2,291.54	4.83%
Gross Margin	96.10%	96.08%	-2bps	95.98%	96.21%	23bps
Operating Cost						
Research and Development (R&D)	488.59	607.82		488.59	607.82	
Sales and Marketing (S&M)	482.74	571.23		494.71	580.23	
General Administration (G&A)	341.19	394.08		325.82	383.60	
Total Expenditure	1,312.52	1,573.13	-19.86%	1,309.12	1,571.65	-20.05%
EBITDA	873.04	711.70	-18.48%	876.85	719.89	-17.90%
EBITDA Margin	38.39%	29.93%	-846bps	38.50%	30.22%	-828bps
Depreciation	144.80	127.95		144.87	128.03	
EBIT	728.24	583.75	-19.84%	731.98	591.86	-19.14%
EBIT Margin	32.02%	24.55%	-747bps	32.14%	24.85%	-729bps
Other Income	182.13	135.12		184.27	135.33	
Profit Before Tax (PBT after exceptional items)	910.37	718.87	-21.04%	916.25	727.19	-20.63%
Exceptional items	0.00	21.64		-	-	
Profit Before Tax	910.37	697.23	-23.41%	916.25	727.19	-20.63%
Tax	242.81	175.33		243.71	176.21	
Profit After Tax (PAT)	667.56	521.90	-21.82%	672.54	550.98	-18.07%
PAT Margin	29.35%	21.95%	-741bps	29.53%	23.13%	-640bps

#### Q3FY22 – Ratio analysis



1 - 0/	Standalone		Consolidated	
In %	Q3FY21	Q3FY22	Q3FY21	Q3FY22
Expenses				
Direct Cost / Revenue	3.68%	4.07%	3.78%	4.07%
R&D / Revenue	23.91%	26.76%	24.34%	26.76%
S&M / Revenue	31.08%	26.57%	32.20%	26.98%
G&A / Revenue	19.18%	16.93%	16.12%	16.47%
Total Cost / Revenue	74.18%	70.25%	72.66%	70.21%
Margin				
Gross Margin	96.32%	95.93%	96.22%	95.93%
EBITDA	22.14%	25.68%	23.56%	25.72%
EBIT	15.17%	19.97%	16.47%	20.02%
PBT	23.93%	24.53%	25.46%	24.58%
PAT	17.89%	17.94%	19.26%	17.94%

#### 9MFY22 – Ratio analysis



L 0/	Standalone		Consolidated	
In %	9MFY21	9MFY22	9MFY21	9MFY22
Expenses				
Direct Cost / Revenue	3.90%	3.92%	4.02%	3.79%
R&D / Revenue	21.48%	25.56%	21.45%	25.52%
S&M / Revenue	21.23%	24.02%	21.72%	24.36%
G&A / Revenue	15.00%	16.57%	14.31%	16.11%
Total Cost / Revenue	57.71%	66.15%	57.48%	65.98%
Margin				
Gross Margin	96.10%	96.08%	95.98%	96.21%
EBITDA	38.39%	29.93%	38.50%	30.22%
EBIT	32.02%	24.55%	32.14%	24.85%
PBT	40.03%	30.23%	40.23%	30.53%
PAT	29.35%	21.95%	29.53%	23.13%

#### **Consolidated Balance Sheet**





<b>EQUITY AND LIABILITIES</b> (₹ mln)	Dec 31, 2020	Dec 31, 2021
Share Holder's Funds:		
Equity Share Capital	642.05	579.55
Share application money pending allotment	-	-
Reserves and Surplus	6,472.75	5,373.69
Total Shareholder Funds	7,114.80	5,953.24
Non-Current Liabilities		
Net employee defined benefit liabilities	3.47	-
Other Non Current Liabilities	-	5.19
Deferred tax liability (net)	-	0.97
Total Non-Current Liabilities	3.47	6.16
Current Liabilities:		
Trade and Other Payables	493.01	526.61
Other Financial Liabilities	30.56	19.17
Other Current Liabilities	135.37	166.78
Net employee defined benefit liabilities	25.59	4.34
Current tax liabilities (Net)	14.18	0.86
Total Current Liabilities	698.71	717.76
Total Equity & Liabilities	7,816.98	6,677.16

	зесиніў зітрініей	1
<b>ASSETS</b> ( <sup>₹</sup> mln)	Dec 31, 2020	Dec 31, 2021
Non-Current Assets:		
Property, plant and equipment	1,408.76	1,330.27
Capital work-in-progress	34.00	2.44
Intangible assets	63.30	64.12
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	174.04	247.48
Loan and Security Deposits	3.82	3.65
Bank Balances	3.40	-
Deferred tax assets (net)	12.49	-
Other non current assets	213.77	204.12
Total Non-Current Assets	1,913.58	1,852.08
Current assets:		
Inventories	32.88	37.41
Investment in Mutual Fund	3,945.08	2,595.89
Trade and other receivables	1,151.87	1,506.47
Bank Balances & Cash and Cash Equivalents	132.97	174.55
Investment in Fixed Deposit	576.63	446.40
Loan and security deposits	7.03	4.38
Interest accrued on FDR & Tax-Free Bonds	12.24	7.52
Other Current assets	44.70	46.92
Assets classified as held for sale	-	5.54
<b>Total Current Assets</b>	5,903.40	4,825.08
Total Assets	7,816.98	6,677.16

#### Standalone Balance Sheet





<b>EQUITY AND LIABILITIES</b> (₹ mln)	Dec 31, 2020	Dec 31, 2021
Share Holder's Funds:		
Equity Share Capital	642.05	579.55
Share application money pending allotment	-	-
Reserves and Surplus	6,512.10	5,388.85
Total Shareholder Funds	7,154.15	5,968.40
Non-Current Liabilities		
Net employee defined benefit liabilities	3.47	-
Other Non Current Liabilities	-	5.19
Deferred tax liability (net)	-	0.97
Total Non-Current Liabilities	3.47	6.16
Current Liabilities:		
Trade and Other Payables	490.83	530.00
Other Financial Liabilities	30.56	19.17
Other Current Liabilities	133.77	165.69
Net employee defined benefit liabilities	25.59	4.34
Current tax liabilities (Net)	13.91	0.71
Total Current Liabilities	694.66	719.91
Total Equity & Liabilities	7,852.28	6,694.47

	security simplified	1
ASSETS (₹ mln)	Dec 31, 2020	Dec 31, 2021
Non-Current Assets:		
Property, plant and equipment	1,408.53	1,329.96
Capital work-in-progress	34.00	2.44
Intangible assets	63.12	63.99
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	296.32	348.12
Loan and Security Deposits	3.82	3.65
Bank Balances	3.40	-
Deferred tax assets (net)	12.49	-
Other non current assets	213.77	204.12
Total Non-Current Assets	2,035.45	1,952.28
Current assets:		
Inventories	32.66	37.38
Investment in Mutual Fund	3,945.08	2,595.89
Trade and other receivables	1,132.78	1,514.03
Bank Balances & Cash and Cash Equivalents	66.61	85.76
Investment in Fixed Deposit	576.63	446.40
Loan and security deposits	6.95	4.28
Interest accrued on FDR & Tax-Free Bonds	12.24	7.52
Other Current assets	43.88	45.39
Assets classified as held for sale	-	5.54
Total Current Assets	5,816.83	4,742.19
Total Assets	7,852.28	6,694.47


#### Working capital analysis



#### At the end of December, 2020\*

#### At the end of September, 2021\*\*

#### At the end of December, 2021\*



#### Note\*

Receivable Days = [(Debtors/ Sales) X (275 days)]

Inventory Days = [(Inventory/Sales) X (275 days)]

Payable Days = [(Creditor/Sales) X (275 days)]

#### Note\*\*

Receivable Days = [(Debtors/ Sales) X (183 days)]

Inventory Days = [(Inventory/Sales) X (183 days)]


Payable Days = [(Creditor/Sales) X (183 days)]

#### Return ratio analysis



#### **Return on Capital Employed\***

#### Return on Equity\*





- > Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
- > Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

**RoCE** = EBIT / Avg. Capital Employed (Equity + Debt)

**Cash Adj. RoCE** = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

**ROE** = PAT / Avg. Equity





### Thank You

#### **Chief Financial Officer**

Mr. Navin Sharma
Navin.Sharma@quickheal.co.in

#### **Company Secretary**

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

CIN No: L72200MH1995PLC091408

www.quickheal.co.in

#### Annexure



#### Products Sold in following countries

- Australia
- Bangladesh
- Benin
- Cambodia
- Canada
- Chile
- Colombia
- Congo
- Ecuador
- El Salvador
- France
- Gambia

- Germany
- Guinea
- Honduras
- Hong Kong
- Italy
- Japan
- Jordan
- Kenya
- Kuwait
- Macao
- Malaysia
- Mauritius

- Mexico
  - Morocco
  - Netherlands
  - New Zealand
  - Nigeria
  - Saudi Arabia
  - Singapore
  - Solomon Islands
  - South Africa
  - South Korea
  - Sri Lanka
  - Panama

- Paraguay
- Peru
- Philippines
- Qatar
- Rwanda
- Thailand
- Turkey
- Uganda
- UAE
- USA
- Venezuela

Mumbai

Chandigarh

New Delhi

Jaipur

Patna

Indore

Surat

Nashik

Nagpur

Lucknow

Guwahati

Ahmedabad

Sales & Support offices across India

- Pune
- Aurangabad
- Kolhapur
- Raipur
- Kolkata
- Bhubaneshwar
- Hyderabad
- Bangalore
- Chennai
- Kochi

